Calfactant for Direct Acute Respiratory Distress Syndrome (CARDS)
Calfactant Therapy for Direct Acute Respiratory Distress Syndrome & Direct Acute Lung Injury in Adults and Children
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
South Australia
-
Adelaide, South Australia, Australia
- Royal Adelaide Hospital
-
-
-
-
British Columbia
-
New Westminster, British Columbia, Canada
- Royal Columbian Hospital
-
Vancouver, British Columbia, Canada
- Vancouver General Hospital
-
Vancouver, British Columbia, Canada
- British Columbia Children's Hospital
-
Vancouver, British Columbia, Canada
- Surrey Memorial Hospital
-
-
Ontario
-
Kingston, Ontario, Canada
- Kingston General Hospital
-
London, Ontario, Canada
- London Health Sciences Centre
-
Ottawa, Ontario, Canada
- Ottawa Hospital
-
-
-
-
-
Jerusalem, Israel
- Haemek Medical Center
-
Jerusalem, Israel
- Rabin Medical Center
-
-
-
-
-
Seoul, Korea, Republic of
- Asan Medical Center
-
Seoul, Korea, Republic of
- Samsung Medical Center
-
-
-
-
-
Auckland, New Zealand
- Starship Children's Hospital
-
-
Auckland
-
Auckland City, Auckland, New Zealand
- Auckland City Hospital
-
-
-
-
Florida
-
Gainesville, Florida, United States
- University of Florida
-
Orlando, Florida, United States
- Florida Hospital and Florida Children's Hospital
-
-
Illinois
-
Chicago, Illinois, United States
- Northwestern University-Chicago
-
Oak Park, Illinois, United States
- West Suburban Hospital Medical Center
-
Peoria, Illinois, United States
- Peoria Pulmonary Associates/OSF St. Francis Hospital
-
-
Indiana
-
Indianapolis, Indiana, United States
- Clarian Health, Inc/Methodist Hospital
-
-
Iowa
-
Iowa City, Iowa, United States
- University of Iowa
-
-
Nebraska
-
Omaha, Nebraska, United States, 68131
- Creighton University
-
Omaha, Nebraska, United States, 68198
- Omaha Children's Hospital
-
-
New Hampshire
-
Lebanon, New Hampshire, United States
- Dartmouth-Hitchcock Medical Center
-
-
New York
-
New York, New York, United States
- Columbia Medical Center--Pediatrics
-
-
Oregon
-
Portland, Oregon, United States
- The Oregon Clinic
-
-
Pennsylvania
-
Hershey, Pennsylvania, United States
- Penn State University
-
-
Texas
-
Houston, Texas, United States
- Baylor College of Medicine/Texas Children's Hospital
-
San Antonio, Texas, United States
- Uthscsa/Stvah
-
-
Virginia
-
Charlottesville, Virginia, United States, 22908
- University of Virginia Health Science Center
-
Fairfax, Virginia, United States
- INOVA Fairfax Hospital
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States
- Medical College of Wisconsin
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Respiratory failure due to diffuse infectious pneumonia, aspiration, near drowning, smoke inhalation or industrial gas
- Less than 48 hours of mechanical ventilation
- Informed consent
Exclusion Criteria:
- Pre-existing lung disease
- coma
- limited therapeutic goals (do not resuscitate, etc.)
- failure of another vital organ
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: 2
|
Administration of 0.5 ml/cm height of air at study entry into the trachea.
Repeat dosing at 12 hours if criteria are met
Other Names:
|
|
Experimental: 1
Calfactant treatment
|
Intratracheal Instillation of 0.5 mL/cm of height of 60 mg/mL suspension in two aliquots at study entry.
Repeat dosing 12 hours later if criteria are met.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Mortality Rate
Time Frame: 90 days
|
90 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Duration of mechanical ventilation
Time Frame: 90 days
|
90 days
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Chair: Douglas Willson, MD, Univeristy of Virginia Health Sciences Center
- Study Chair: Jonathon Truwit, MD, University of Virginia Health Sciences Center
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Respiratory Tract Diseases
- Respiration Disorders
- Lung Diseases
- Disease
- Infant, Newborn, Diseases
- Lung Injury
- Infant, Premature, Diseases
- Syndrome
- Respiratory Distress Syndrome
- Respiratory Distress Syndrome, Newborn
- Acute Lung Injury
- Respiratory System Agents
- Pulmonary Surfactants
- Calfactant
Other Study ID Numbers
Other Study ID Numbers
- Pneuma AR-06
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.